Growing out of the research undertaken by the firm's President while at University of Wisconsin Madison, Scarab Genomics, LLC is focussed on the commercialization of the Clean Genome® Multiple Deletion Series (MDS) E. colí. The firm licensed the patented reduced genome technology from Wisconsin Alumni Research Foundation on an exclusive, worldwide basis. Clean Genome® E. colí was bioengineered by deleting over 15% of the K-12 genome. Using synthetic biology methods, a series of precise deletions were made, including the elimination of non-essential genes, recombinogenic and mobile DNA, and cryptic virulent genes. Genome reduction optimizes these E. colí strains for production, providing enhanced genetic stability and improved metabolic efficiency. Clean Genome® E. colí are the strains of choice for a wide spectrum of applications ranging from routine cloning to large scale production of biopharmaceuticals.
